Detecting Recurrent Prostate Cancer With 11C-choline Positron Emission Tomography

Inclusion Criteria:

- Patient must have biopsy-proven adenocarcinoma of the prostate initially treated with
curative intent (surgery and radiation therapy are most common treatments but other
treatments are also eligible).

- Biochemical recurrence defined as any of the following:

1. PSA ≥ 0.2 ng/mL in at least two sequential tests for patients treated with
surgery.

2. PSA ≥ 0.2 ng/mL above the post therapy nadir for patients treated with radiation
therapy, brachytherapy or cryotherapy.

3. PSA ≥ 0.2 ng/ml above the most recent therapy nadir for patients who have
received additional treatment in the recurrent setting

- Patient must have undergone standard-of-care restaging that does not clearly identify
site(s) of active disease, or such prior studies must show equivocal findings for
which further work-up is considered necessary to make clinical decision. Standard
staging examinations may include one or more of the following: CT or MRI, bone imaging
(either Tc-99m bisphosphonate scintigraphy MDP or F-18 sodium fluoride PET), FDG PET,
or In-111 capromab pendetide scintigraphy no older than 3 months of consent date.

- Age ≥ 18 years.

- Patient must be able to tolerate PET/CT imaging.

- Patient must be able to understand and willing to sign a written informed consent
document.

Exclusion Criteria:

- Patient must not have claustrophobia that would preclude PET/CT imaging or other
contraindications to CT imaging.